CoChat
Sign Up
Cited by 269

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

An Assessment of Statin Safety by Hepatologists

Cohen, David E., Anania, Frank A., Chalasani, Naga·2006·The American Journal of Cardiology
DOI 10.1016/j.amjcard.2005.12.014
Open this paper in CoChat — free account

Abstract

The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2005.12.014

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 18

  1. Chalasani, 2005, Statins and hepatotoxicity, Hepatology, 41, 690, 10.1002/hep.20671 · DOI
  2. Mofrad, 2003, Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values, Hepatology, 37, 1286, 10.1053/jhep.2003.50229 · DOI
  3. Sniderman, 2004, Is there value in liver function test and creatine phosphokinase monitoring for statin use?, Am J Cardiol, 94, 30F, 10.1016/j.amjcard.2004.07.052 · DOI
  4. Vuppalanchi, 2005, Patients with elevated baseline liver enzymes do not have higher frequency of hepatoxicity from lovastatin than those with normal baseline liver enzymes, Am J Med Sci, 329, 62, 10.1097/00000441-200502000-00002 · DOI · Paper page
  5. Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 126, 1287, 10.1053/j.gastro.2004.02.015 · DOI · Paper page
  6. de Denus, 2004, Statins and liver toxicity, Pharmacotherapy, 24, 584, 10.1592/phco.24.6.584.34738 · DOI
  7. Russo, 2004, Liver transplantation for acute liver failure from drug induced liver injury in the United States, Liver Transpl, 10, 1018, 10.1002/lt.20204 · DOI · Paper page
  8. Gotto, 2003, Safety and statin therapy. Reconsidering the risks and benefits, Arch Intern Med, 163, 657, 10.1001/archinte.163.6.657 · DOI
  9. Pelli, 2003, Autoimmune hepatitis revealed by atorvastatin, Eur J Gastroenterol Hepatol, 15, 921, 10.1097/00042737-200308000-00014 · DOI
  10. Siddiqui, 2005, Autoimmune hepatitis induced by statins, Gastroenterology, 128, A171
  11. Tolman, 2002, The liver and lovastatin, Am J Cardiol, 89, 1374, 10.1016/S0002-9149(02)02355-X · DOI
  12. Smith, 2003, Screening for statin-related toxicity, Arch Intern Med, 163, 688, 10.1001/archinte.163.6.688 · DOI
  13. Sandler, 2002, The burden of selected digestive diseases in the United States, Gastroenterology, 122, 1500, 10.1053/gast.2002.32978 · DOI · Paper page
  14. Neuschwanter-Tetri, 2003, Nonalcoholic steatohepatitis, Hepatology, 37, 1202, 10.1053/jhep.2003.50193 · DOI
  15. Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis, Atherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008 · DOI
  16. Horlander, 2001, Atorvastatin for the treatment of NASH [abstract], Gastroenterology, 120, A544, 10.1016/S0016-5085(08)82704-7 · DOI
  17. Kiyici, 2003, Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis, Can J Gastroenterol, 17, 713, 10.1155/2003/857869 · DOI
  18. Bjornsson, 2005, Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Cohen, D. E., Anania, F. A., & Chalasani, N.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2006-04
Volume
97
Issue
8
Pages
S77-S81
ISSN
0002-9149
DOI
10.1016/j.amjcard.2005.12.014
Cited by
269
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review